Pharmaceutical sponsor
Galderma R&D Clinical Trials
Studies where Galderma R&D is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 10Midface Volume Deficit, Midface Contour Deficiency
A Study to Evaluate the Long-term Safety and Effectiveness of Sculptra™
This is a non-interventional, multi-center, study designed to evaluate the long-term safety and effectiveness of Sculptra™ for the correction of midface volume deficit and/or midface contour deficiency in subjects of Chinese…
- Trial name
- NCT07891767
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Galderma R&D
Atopic Dermatitis
Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis
This is a bridging study only for Chinese subjects. The goal of this clinical trial is to learn if drug Nemolizumab works to treat moderate to severe AD in over 12 years old male and female.
- Trial name
- NCT07762833
- Testing
- Nemolizumab 30 mg
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Galderma R&D
Jawline Definition
A Study to Evaluate the Effectiveness and Safety of Restylane Shaype in the Improvement of Jawline Definition
This is a randomized, evaluator-blinded, parallel group, no-treatment controlled, multicenter study to evaluate effectiveness and the safety of Restylane Shaype for improvement of jawline definition in China.
- Trial name
- NCT07805512
- Testing
- Restylane Shaype
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Galderma R&D
Prurigo Nodularis
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.
- Trial name
- RE-UNITE PN (NCT06988618)
- Where
- 51 sites in United States, Germany
- Volunteers
- 600 people
- Sponsor
- Galderma R&D
Chin Augmentation
Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region
The primary objective of this study is to evaluate the safety of Restylane Lyft with Lidocaine for augmentation of the chin region 3 months after retreatment.
- Trial name
- NCT07566286
- Testing
- Restylane Lyft with Lidocaine
- Where
- 8 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Moderate-to-Severe Atopic Dermatitis
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis
The primary objective of the study is to assess the pharmacokinetics (PK) and safety of nemolizumab in pediatric participants (aged 6-23 months) with moderate-to-severe atopic dermatitis (AD) who are not adequately controlled…
- Trial name
- NemoBaby (NCT07660835)
- Testing
- Nemolizumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Galderma R&D
Systemic Sclerosis
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
The main purpose of the study is to investigate the efficacy on cutaneous thickness and the safety of Nemolizumab in adult patients with systemic sclerosis after a 52-week treatment period and to select the optimal dose for this…
- Trial name
- NCT07047690
- Testing
- Nemolizumab
- Where
- 3 sites in United States, Switzerland
- Volunteers
- 162 people
- Sponsor
- Galderma R&D
Atopic Dermatitis
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
- Trial name
- RE-UNITE AD (NCT06988605)
- Where
- 108 sites in United States, Germany and 1 more
- Volunteers
- 1,000 people
- Sponsor
- Galderma R&D
Volume Deficiency in the Mid-Face, Skin Laxity
A Study to Characterize Human Skin Changes From Biostimulator Treatments Via Non-invasive Imaging
Adult subjects with moderate-to-severe cheek wrinkles will be treated with Sculptra for correction of fine lines and wrinkles in the cheek area.
- Conditions
- Volume Deficiency in the Mid-Face, Skin Laxity, Photo-aged Skin
- Trial name
- NCT07399028
- Testing
- Sculptra®
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Galderma R&D
Cheek Wrinkles, Menopausal Women
A Clinical Study to Assess Histological Changes From Treatment of Poly L-lactic Acid Biostimulator on Women at Various Menopausal Stages
To assess protein expression stimulated by poly L-lactic acid (PLLA) via punch biopsy at each follow-up visits compared to Baseline.
- Trial name
- NCT07342400
- Testing
- Sculptra®
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Galderma R&D
Completed, with results posted
All 199Wrinkle
Main Study: A Study to Evaluate the Effectiveness and Safety of GAL1906 for Correction of Wrinkles in the décolletage Area Sub-study: A Follow-up Study to Evaluate the Analysis of Mammograms Following Treatment for Correction of Wrinkles in Décolletage Area in the Investigational Study 43USRV1906
Main study: Randomized, evaluator-blinded, no treatment controlled multicenter study to evaluate safety and effectiveness of GAL1906 for the correction of wrinkles in the décolletage area.
- Trial name
- NCT04717934
- Testing
- GAL1906
- Where
- 14 sites in United States
- Volunteers
- 211 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Moderate-to-Severe Atopic Dermatitis
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study was to assess the pharmacokinetics (PK), safety, and efficacy of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT04921345
- Testing
- Nemolizumab
- Where
- 23 sites in United States, Denmark and 3 more
- Volunteers
- 109 people
- Sponsor
- Galderma R&D
Non-facial Skin Aesthetic Conditions
Sculptra Chart Review
Multi-center retrospective chart review to evaluate the safety of Sculptra Aesthetic when used in non-facial areas
- Trial name
- NCT05463978
- Testing
- Sculptra Aesthetic
- Where
- 8 sites in United States
- Volunteers
- 498 people
- Sponsor
- Galderma R&D
Plaque Psoriasis, Psoriasis
A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients
Subjects having mild-to-severe plaque psoriasis, with active target lesion plaques, and currently on or starting a prescription treatment for plaque psoriasis will apply a topical skincare regimen to one side of the body.
- Trial name
- NCT06357221
- Testing
- Cetaphil
- Where
- 3 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Dermatitis, Atopic
A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab
The purpose of this study is to assess the effect of nemolizumab (CD14152) on humoral immune responses to tetanus and meningococcal vaccination in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT04365387
- Testing
- Nemolizumab
- Where
- 64 sites in United States
- Volunteers
- 242 people
- Sponsor
- Galderma R&D